| scholarly article | Q13442814 |
| P50 | author | Oliver Zivanovic | Q91946584 |
| Ginger J. Gardner | Q91946587 | ||
| Carol Aghajanian | Q91946596 | ||
| Ane Gerda Zahl Eriksson | Q92269733 | ||
| Nadeem R. Abu-Rustum | Q99678175 | ||
| Jennifer J Mueller | Q59545879 | ||
| Douglas A Levine | Q86514653 | ||
| Yukio Sonoda | Q88607034 | ||
| Roisin E. O'Cearbhaill | Q90697657 | ||
| Alexia Iasonos | Q91946576 | ||
| Dennis Chi | Q91946580 | ||
| P2093 | author name string | Qin C Zhou | |
| Farah A Alvi | |||
| Amr El Haraki | |||
| P2860 | cites work | Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 | Q30360249 |
| Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study | Q33331105 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer | Q35294575 | ||
| A framework for a personalized surgical approach to ovarian cancer | Q35926352 | ||
| Development and assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events grading system. | Q36344889 | ||
| Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. | Q36443934 | ||
| 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference | Q37872164 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. | Q41721778 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR). | Q45917180 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. | Q51174141 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Neoadjuvant chemotherapy for advanced ovarian cancer | Q72401880 | ||
| Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer | Q74202977 | ||
| Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma | Q77357035 | ||
| Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis | Q80019806 | ||
| The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer | Q81586923 | ||
| Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm | Q83733281 | ||
| The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists | Q84624013 | ||
| An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) | Q84943384 | ||
| Is the easier way ever the better way? | Q84964367 | ||
| Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment | Q85174042 | ||
| Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr | Q87259669 | ||
| A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer | Q87416739 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 436-442 | |
| P577 | publication date | 2016-01-08 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center | |
| P478 | volume | 140 |
| Q92432547 | CLINICAL PROGNOSTIC FACTORS IN PRE- AND POST-MENOPAUSAL WOMEN WITH OVARIAN CARCINOMA |
| Q91043335 | CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy |
| Q50055414 | Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. |
| Q91946612 | Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery |
| Q92398001 | Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery |
| Q91045719 | Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? |
| Q47257079 | Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase |
| Q37683243 | Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. |
| Q90107776 | Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? |
| Q49337608 | Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study |
| Q57174233 | Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives |
| Q48709352 | Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors |
| Q99563761 | Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment |
| Q39332785 | Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center |
| Q57212815 | It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer |
| Q88015812 | Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer |
| Q30253028 | Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). |
| Q87899667 | Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection |
| Q94450908 | NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis |
| Q50157919 | PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process |
| Q96297778 | Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk? |
| Q58751209 | Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals |
| Q90423732 | Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer |
| Q36347700 | Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer |
| Q91024536 | Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery |
| Q93033966 | State of the science: Evolving role of surgery for the treatment of ovarian cancer |
| Q49894154 | Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival? |
| Q95837318 | Surgical training in gynecologic oncology: Past, present, future |
| Q51809291 | Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. |
| Q55008645 | The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. |
| Q97691128 | The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance |
| Q39441629 | The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes |
| Q89180680 | Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review |
| Q50420488 | Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis |
| Q38861953 | Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. |
Search more.